Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forbes Medi-Tech Inc.

Latest From Forbes Medi-Tech Inc.

Private Biotech M&A Review: Has the Market Lost Steam?

In a still-frozen IPO market, acquisition has become the go-to exit for biotech VCs, but an analysis of the past four years' deals suggests the market may have peaked. Of more than 180 private biotech acquisitions since 2005, fewer than half in each year resulted in a reliable exit for investors, and those numbers are trending downward. Although the most active acquirers amounted to a list of the usual suspects, the bulk of acquisitions were conducted by a diverse set of smaller public and still-private firms. We also review the characteristics of those companies that have had success in terms of good exits for investors.
BioPharmaceutical Strategy

Forbes sells its pharma business to Transition

Forbes Medi-Tech has sold its San Diego-based pharmaceutical business unit to Transition Therapeutics after announcing in May that it would be abandoning its in-house drug development activities.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Nutraceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Forbes Medi-Tech Inc.
  • Senior Management
  • Charles A Butt, Pres. & CEO
    David Goold, CFO
    Jeff Motley, VP, Comm. Oper.
    Laura Wessman, SVP, Operations
  • Contact Info
  • Forbes Medi-Tech Inc.
    Phone: (604) 689-5899
    750 West Pender St. Ste. 200
    Vancouver, V6C 2T8